Form 4: Regulus Therapeutics Director Disposes Shares Following Novartis Acquisition Completion

Regulus Therapeutics Inc. director William H. Rastetter has disposed of his common stock and derivative securities as the company completed its merger, becoming a wholly-owned subsidiary of Novartis AG.

Summary

• William H. Rastetter, a Director of Regulus Therapeutics Inc. (RGLS), reported the disposition of his beneficial ownership in the company's securities.
• The disposition occurred on June 25, 2025, coinciding with the effective time of the merger between Regulus Therapeutics Inc. and Redwood Merger Sub Inc., a wholly-owned indirect subsidiary of Novartis AG.
• Under the Merger Agreement dated April 29, 2025, each share of Regulus common stock was exchanged for an 'Offer Price' consisting of $7.00 in cash (the 'Closing Amount') plus one Contingent Value Right (CVR).
• Each CVR represents the right to receive an additional contingent payment of $7.00 in cash upon the achievement of a specified milestone.
• Mr. Rastetter disposed of 44,264 shares of common stock held directly and 57,292 shares held indirectly through The Rastetter Family Trust, all in exchange for the Offer Price.
• Restricted stock units held indirectly (57,292 units) were canceled and converted into cash equal to the product of the number of shares underlying the RSU and the Closing Amount, plus one CVR per share.
• In-the-Money Stock Options (exercise price less than $7.00) were canceled and converted into a cash payment equal to (Closing Amount exercise price) multiplied by the number of underlying shares, plus one CVR per share.
• Out-of-the-Money Stock Options (exercise price equal to or greater than $7.00 but less than $14.00) were canceled and converted into one CVR per share, with a potential future cash payment if the CVR milestone is met.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as the merger provides a definitive cash exit for shareholders, with additional potential upside via the CVR. However, the contingent nature of the CVR introduces an element of uncertainty, preventing a 'strong buy' sentiment.

Positives

• The merger provides a clear exit strategy for Regulus Therapeutics shareholders, offering an immediate cash component of $7.00 per share.
• The inclusion of a Contingent Value Right (CVR) offers shareholders potential upside of an additional $7.00 per share if a specific milestone is achieved, aligning shareholder interests with future drug development success under Novartis.

Negatives

• Regulus Therapeutics Inc. ceases to be an independent publicly traded company, limiting future direct investment opportunities in its standalone operations.
• The full value of the acquisition, specifically the additional $7.00 per share from the CVR, is contingent upon the achievement of a future milestone, which is not guaranteed.

Risks

• The Contingent Value Right (CVR) payment of $7.00 per share is contingent upon the achievement of a specific milestone, and there is no guarantee that this milestone will be met, meaning the CVR may not result in any payment.
• The value of the CVR is subject to the terms and conditions set forth in the CVR Agreement, which may include various risks related to drug development, regulatory approvals, and commercialization.

Future Outlook

Regulus Therapeutics Inc. is now a wholly-owned subsidiary of Novartis AG. The future financial outcome for former shareholders is tied to the potential achievement of the CVR milestone, which would trigger an additional $7.00 cash payment per CVR.

Management Comments

• The document details actions taken pursuant to the Agreement and Plan of Merger, dated April 29, 2025, and the subsequent completion of the cash tender offer and merger.

Industry Context

This acquisition reflects a common trend in the pharmaceutical and biotechnology industry where larger companies like Novartis acquire smaller biotechs, often to gain access to promising drug pipelines or specific therapeutic platforms. The use of Contingent Value Rights (CVRs) is a frequent mechanism in such deals to bridge valuation gaps and share the risk/reward of future clinical or regulatory milestones.

Comparison to Industry Standards

• The acquisition structure, combining an upfront cash payment with a contingent value right (CVR), is a common approach in biotech mergers and acquisitions, particularly when the target company has pipeline assets with significant but unproven future value.
• Similar CVR structures have been observed in other pharmaceutical acquisitions, such as Sanofi's acquisition of Kadmon Holdings or Bristol Myers Squibb's acquisition of MyoKardia, where contingent payments were tied to regulatory approvals or sales milestones.
• The $7.00 upfront cash plus a potential $7.00 CVR provides a total potential value of $14.00, which can be assessed against the target company's pre-announcement market capitalization and the perceived value of its intellectual property and pipeline assets relative to comparable transactions in the sector.

Related Party Transactions

• The document reports the disposition of common stock and derivative securities by William H. Rastetter, a Director of Regulus Therapeutics Inc., as a result of the company's acquisition by Novartis AG. This is an insider transaction related to the change of control.

Stakeholder Impact

• Shareholders: Received $7.00 cash per share and one CVR per share, with potential for an additional $7.00 per CVR upon milestone achievement.
• Employees (with equity): Equity awards (restricted stock units and stock options) were converted into cash and CVRs based on the merger terms.
• Company (Regulus Therapeutics Inc.): Ceased to be an independent public entity and became a wholly-owned subsidiary of Novartis AG.

Next Steps

• Achievement of the milestone specified in the CVR Agreement to trigger the contingent payment of $7.00 per CVR.

Key Dates

Keywords

Regulus Therapeutics, Novartis, Merger, Acquisition, SEC Form 4, Insider Transaction, Stock Options, Contingent Value Right, CVR, RGLS, Biotechnology, Pharmaceuticals